Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Preventive treatment with Soliris helps in kidney transplant in aHUS

Preventive treatment with Soliris (eculizumab) before surgery dramatically improved kidney transplant outcomes in people with atypical hemolytic uremic syndrome (aHUS), according to a recent study. One year after the surgeries, 97% of transplanted kidneys still functioned in Soliris-treated patients. In those who did not receive preventive treatment, that…

Phase 2 Trial of NM8074 in aHUS Patients Cleared to Open by FDA

NovelMed has been cleared to begin patient testing of NM8074, an investigational antibody-based therapy for atypical hemolytic uremic syndrome (aHUS) that is not expected to carry a risk of treatment-related infections. The therapy candidate is designed to block the complement cascade — a part of the immune system…

Case Report: Uterine Fibroid Surgery Triggers aHUS in Woman

Uterine fibroid surgery triggered atypical hemolytic uremic syndrome (aHUS) in a woman without disease-related genetic defects, a case study reported. Clinicians should investigate conditions such as aHUS after major gynecologic surgery accompanied by kidney impairment and abnormal lab tests indicating red blood cell damage to prevent irreversible kidney disease,…